The initiation of coagulation results from the activation of factor X by an enzyme complex (Xase) composed of the trypsin-like serine proteinase, factor VIIa, bound to tissue factor (TF) on phospholipid membranes. We have investigated the basis for the protein substrate specificity of Xase using TF reconstituted into vesicles of phosphatidylcholine, phosphatidylserine, or pure phosphatidylcholine. We show that occupation of the active site of VIIa within Xase by a reversible inhibitor or an alternate peptidyl substrate is sufficient to exclude substrate interactions at the active site but does not alter the affinity of Xase for factor X. This is evident as classical competitive inhibition of peptidyl substrate cleavage but as classical noncompetitive inhibition of factor X activation by active site-directed ligands. This implies that the productive recognition of factor X by Xase arises from a multistep reaction requiring an initial interaction at sites on the enzyme complex distinct from the active site (exosites), followed by active site interactions and bond cleavage. Exosite interactions determine protein substrate affinity, whereas the second binding step influences the maximum catalytic rate for the reaction. We also show that competitive inhibition can be achieved by interfering with exosite binding using factor X derivatives that are expected to have limited or abrogated interactions with the active site of VIIa within Xase. Thus, substrate interactions at exosites, sites removed from the active site of VIIa within the enzyme complex, determine affinity and binding specificity in the productive recognition of factor X by the VIIa-TF complex. This may represent a prevalent strategy through which distinctive protein substrate specificities are achieved by the homologous enzymes of coagulation.
The initiation of coagulation results from the activation of factor X by an enzyme complex (Xase) composed of the trypsin-like serine proteinase, factor VIIa, bound to tissue factor (TF) on phospholipid membranes. We have investigated the basis for the protein substrate specificity of Xase using TF reconstituted into vesicles of phosphatidylcholine, phosphatidylserine, or pure phosphatidylcholine. We show that occupation of the active site of VIIa within Xase by a reversible inhibitor or an alternate peptidyl substrate is sufficient to exclude substrate interactions at the active site but does not alter the affinity of Xase for factor X. This is evident as classical competitive inhibition of peptidyl substrate cleavage but as classical noncompetitive inhibition of factor X activation by active site-directed ligands. This implies that the productive recognition of factor X by Xase arises from a multistep reaction requiring an initial interaction at sites on the enzyme complex distinct from the active site (exosites), followed by active site interactions and bond cleavage. Exosite interactions determine protein substrate affinity, whereas the second binding step influences the maximum catalytic rate for the reaction. We also show that competitive inhibition can be achieved by interfering with exosite binding using factor X derivatives that are expected to have limited or abrogated interactions with the active site of VIIa within Xase. Thus, substrate interactions at exosites, sites removed from the active site of VIIa within the enzyme complex, determine affinity and binding specificity in the productive recognition of factor X by the VIIa-TF complex. This may represent a prevalent strategy through which distinctive protein substrate specificities are achieved by the homologous enzymes of coagulation.
The proteolytic activation of factor X by the extrinsic pathway is considered the initiating step of the blood coagulation cascade following vascular damage (4 -7) . The conversion of the zymogen, factor X, to the serine protease, factor Xa, is accomplished by the extrinsic Xase complex that assembles through reversible interactions between the serine proteinase, factor VIIa, and the integral membrane cofactor protein, tissue factor (TF) 1 (4, 5) . Although this complex can catalyze the proteolytic activation of either factors X or IX to their respective active enzymes with comparable catalytic efficiency, Xa formation is considered essential for the initiation of the coagulation cascade, whereas IXa formation may be important for sustained flux toward thrombin formation (4 -7) .
The catalytic domains of the serine proteinases of coagulation are highly homologous to each other as well as to trypsin, the archetypical arginine-specific serine proteinase (8, 9) . Despite these similarities, the coagulation proteinases act on their protein substrates with narrow and distinctive specificity (10) . The molecular basis for the defined protein substrate specificity of the coagulation enzyme complexes is not well understood. It is implicitly assumed that protein substrate specificity arises from specific binding interactions between the active site of the enzyme and distinctive peptidyl sequences surrounding the scissile bond. In the case of the reactions of VIIa-TF, this assumption is generally supported by similarities between the residues preceding the scissile bonds in both IX and X (11) .
A series of mutagenesis and antibody inhibition studies have suggested a role for extended interactions between factor X and surfaces in both VIIa and TF in factor X activation. Evidence supports a direct interaction between the ␥-carboxyglutamic acid containing domain in the N terminus of the factor X light chain and regions of the VIIa-TF complex adjacent to the membrane surface (12) (13) (14) (15) (16) . Antibody inhibition studies have implicated residues in the protease domain of VIIa, removed from the catalytic site, in contributing to the cleavage of factor X (17) . Since the activation peptide at the N terminus of the heavy chain of factor X is released upon cleavage and residues N-terminal to the P 3 2 site in the substrate do not significantly contribute to factor X activation (18) , it is possible that the extended interactions between the substrate and the VIIa-TF complex involve structural determinants common to both factors X and Xa. However, an interaction between Xa and the VIIa-TF complex has yet to be demonstrated.
Specific protein substrate recognition through extended macromolecular interaction sites (exosites) has been documented in the case of the analogous prothrombinase complex of coagulation (19) . Exosite-dependent substrate recognition implies that extended surfaces on the enzyme complex, distinct from residues surrounding the catalytic site, contribute to substrate affinity by favoring productive interactions between enzyme and substrate. The recent demonstration that an uncleavable form of factor X with the P 1 arginine substituted with glutamine can act as a competitive inhibitor of factor X activation with a K i comparable to the measured K m for factor X favors a role for exosite interactions in VIIa-TF function (20) . However, these conclusions have been based on kinetic studies using VIIa-TF assembled on membranes that support the high affinity binding of factor X (21) . Under these conditions, the energetics of the factor X-membrane interaction are established to dominate the inferred affinity of the substrate for the enzyme (22) . This is evident from the fact that membrane-binding proteins with no known interaction with VIIa-TF act as competitive inhibitors of factor X activation (22) . Thus, the contribution of exosite-dependent protein-protein interactions between VIIa-TF and factor X to the affinity of the enzyme for the substrate remains unclear.
More recently, a structural biology approach has provided new evidence showing that peptide binding to regions of the factor VIIa-protease domain distinct from the active site can lead to the inhibition of factor X activation by the VIIa-TF complex (23) . Peptide binding to this site was shown to lead to noncompetitive inhibition of factor X activation by VIIa-TF and partial inhibition of peptidyl substrate cleavage (23) . Whereas this approach has convincingly established that the occupation of sites on the protease removed from the catalytic residues can modulate active site function, it does not satisfactorily address the question of whether extended macromolecular interactions between VIIa-TF and factor X significantly impact the binding specificity for the protein substrate.
These independent lines of evidence leave little doubt that extended surfaces in the VIIa-TF complex participate in its function. However, the precise contribution of substrate interactions with such enzymic exosites to the binding affinity for factor X is unclear. Studies of protein substrate cleavage by prothrombinase have yielded a general and facile approach for the assessment of the functional significance of exosite interactions in protein substrate recognition (19) . We have extended this approach to studies of factor X activation by the VIIa-TF complex to assess the relative contributions of active site versus exosite interactions in enzymic function.
EXPERIMENTAL PROCEDURES
Materials-Hepes, L-␣-phosphatidylcholine (PC), L-␣-phosphatidylserine (PS), soybean trypsin inhibitor-Sepharose, and p-amidinophenylmethanesulfonyl fluoride (APMSF) were from Sigma. Polyethylene glycol, M r ϭ 8000 (PEG-8000), was from J. T. Baker Inc.; 4-aminobenzamidine (PAB) was from Aldrich; n-octyl-␤-D-glucopyranoside was from Calbiochem, and benzamidine-Sepharose was from Amersham Pharmacia Biotech. Patient plasma obtained by plasmapheresis was donated by the plasmapheresis laboratory of Emory University Hospital or by the Apheresis Unit of the Hospital of the University of Pennsylvania. The peptidyl substrate methoxycarbonyl-cyclohexyl-glycyl-glycyl-L-arginyl-p-nitroanilide (Spectrozyme Xa, SpXa) was obtained from American Diagnostica (Greenwich, CT), and the factor VIIa substrate, methylsulfonamide-D-phenylalanyl-L-prolyl-L-arginyl-para-nitroanilide (Corvas-pNA), was a generous gift of Dr. George Vlasuk, CORVAS, San Diego. Stock solutions of either peptidyl substrate (ϳ4 mM) were prepared in water, and the concentration was determined using E 342 ϭ 8270 M Ϫ1 ⅐cm Ϫ1 (24) . The concentration of PAB was determined using E 295 ϭ 15,000 M Ϫ1 ⅐cm Ϫ1 (25) . All kinetic studies were performed in 20 mM Hepes, 0.15 M NaCl, 5 mM CaCl 2 , 0.1% (w/v) PEG-8000, pH 7.50 (designated as Assay Buffer). Continuous and discontinuous kinetic studies were performed using 96-well plates (Corning 9710, Corning, NY) pretreated with Tween 20 and air-dried prior to use as described previously (26) to minimize adsorption artifacts.
Proteins-Human factor X was purified following barium citrate adsorption of plasma using methods described previously (18) . The zymogen preparation was depleted of traces of active Xa as described (26) . Factor X was proteolytically activated to factor Xa using the purified X activator isolated from Russell's viper venom and further purified by affinity chromatography on benzamidine-Sepharose (27) . The concentration of active sites, determined by kinetic titration with p-nitrophenyl pЈ-guanidinobenzoate (28) , ranged between 0.95 and 1.1 mol active site/mol protein for several preparations. Catalytically inactive Xa (Xa i ) was prepared by treating Xa with APMSF. A solution of factor Xa (11 M, 6 mg) in 20 mM Hepes, 0.15 M NaCl, 0.1% (w/v) PEG-8000, pH 7.5, was treated with sequential additions of 100 M APMSF followed by incubation at room temperature for 5 min at each cycle. At the end of 5 cycles, the initial velocity of SpXa cleavage was reduced by 99.97%. The resulting material was applied sequentially to benzamidine-Sepharose and soybean trypsin inhibitor-Sepharose to remove traces of active factor Xa, dialyzed into 20 mM Hepes, 0.15 M NaCl, pH 7.5, and concentrated by ultrafiltration to yield an ϳ60 M solution of Xa i . Residual active Xa in the Xa i preparation was estimated at ϳ0.008 mol % by initial velocity measurements of SpXa cleavage.
A mutant derivative of recombinant human factor X containing Ser 195 replaced with Ala and Arg 15 replaced with Gln (hereafter termed X R15Q ) 3 was expressed in mammalian cells, purified, and characterized as described previously (20) . The derivative was further purified by gel filtration using a 2.5 ϫ 120-cm column of Sephacryl S-300 (Amersham Pharmacia Biotech) equilibrated in 20 mM Hepes, 0.15 M NaCl, pH 7.5. Fractions containing factor X R15Q were concentrated by ultrafiltration, dialyzed into 20 mM Hepes, 0.15 M NaCl, 0.1% (w/v) PEG-8000, pH 7.5, and stored frozen at Ϫ20°C.
Recombinant human factor VIIa was purchased from Novo-Nordisc (Gentofte, Denmark). Recombinant human tissue factor (residues 1-243) was obtained as a gift from Genentech (South San Francisco, CA). TF apoprotein was reconstituted into membrane vesicles either containing 100% PC or 75% (w/w) PC plus 25% (w/w) PS (PCPS) using n-octyl-␤-D-glucopyranoside followed by dialysis at a controlled rate as described previously (29) . Following exhaustive dialysis, the preparations were centrifuged (50,000 ϫ g, 30 min) to remove multilamellar and aggregated products. The resulting supernatant was characterized for total TF recovery, phospholipid content, and vesicle size and polydispersity by quasielastic light scattering as described previously in detail, to yield the concentrations of TF, monomeric phospholipid, and vesicles (26) . For some preparations, the accessible and functional concentration of TF was inferred from measurements of the rate of peptidyl para-nitroanilide cleavage in the presence of increasing concentrations of factor VIIa (30) . Within experimental error, this approach yielded equivalent results to TF recovery measurements based on 125 I-labeled TF added as a tracer to the initial reaction mixture and assuming that one-half the TF molecules are correctly oriented in the vesicles (26, 31) . The resulting preparations of TF incorporated into PCPS (TF/PCPS) or into PC (TF/PC) reflect vesicles (d Х 160 -220 nm) containing at least one functional TF/vesicle. The concentration of TF is reported in terms of the total functional TF accessible to interact with added factor VIIa.
The purity of all protein preparations was evaluated by SDS-polyacrylamide gel electrophoresis (32) . Protein concentrations were evaluated using the following molecular weights and extinction coefficients (E 280 0.1% ): human X, 56,500, 1.16 (33); human Xa, 45,300, 1.16 (33) ; and human recombinant VIIa, 50,000, 1.39 (34) .
Inhibition of Peptidyl Substrate Cleavage by VIIa-TF-Mixtures (100 l) containing increasing concentrations of Corvas-pNA in Assay Buffer with different fixed concentrations of PAB were prepared in wells of a 96-well plate. Because the substrate stock solution was prepared in water, an appropriate volume of a 10ϫ Assay Buffer solution adjusted to pH 7.75 was added to each mixture to ensure that the final pH and concentration of buffer solutes was invariant. These reaction mixtures were initiated with an equal volume of preassembled enzyme to achieve a final concentration of 5 nM VIIa, and 7.5 nM TF incorporated into either PC or PCPS vesicles. After mixing by brief vibration, initial steady state rates of Corvas-pNA cleavage were measured by continuously monitoring absorbance at 405 nm using either a V max or a SpectraMax 250 kinetic plate reader (Molecular Devices, Menlo Park, CA). When the catalyst was assembled using TF/PCPS, precipitation of Corvas-pNA was noted at high substrate concentrations (Ͼ600 M) that depended on the concentration of Ca 2ϩ and PCPS. Substrate precipitation could be avoided by using TF/PCPS reconstituted at high TF densities (ϳ40 TF/vesicle) to reduce the final concentration of PCPS in the reaction mixture. This manipulation had no obvious effect on the rate of peptidyl substrate hydrolysis at substrate concentrations of 500 M or lower.
Inhibition Studies of Factor X Activation-Initial velocities for factor X activation were obtained from discontinuous measurements of factor Xa formation following the procedures described previously (18) . Factor X was exchanged into Assay Buffer before use by column centrifugation, using a syringe column packed with Sephadex G-25 (Amersham Pharmacia Biotech) and equilibrated in the same buffer. Reaction mixtures (60 l) in wells of a 96-well plate contained increasing concentrations of factor X with different fixed concentrations of the inhibitor to be tested. Factor X activation was initiated by adding an equal volume of enzyme solution containing VIIa preincubated with TF/PCPS or TF/PC in the same buffer to achieve the indicated final concentrations of all reactants. The reaction was allowed to proceed either at ambient temperature or in a thermostatted block (Thermomixer R, Eppendorf, Westbury, NY) maintained at 25°C with mixing ensured by periodic vibration. Aliquots (10 l) were withdrawn at various times (0, 20, 40, 60, 90, 120, and 180 s) following initiation and quenched by mixing with 90 l of 20 mM Hepes, 0.15 M NaCl, 0.1% (w/v) PEG-8000, 50 mM EDTA, pH 7.5. Quenched samples were diluted further in the same buffer, and the initial velocity of SpXa hydrolysis was measured spectrophotometrically following the addition of 100 M SpXa. The concentration of factor Xa formed as a function of time was determined by interpolation from the linear dependence of the initial rate of SpXa hydrolysis on known concentrations of factor Xa determined separately with each experiment. The initial, steady state rate of factor Xa formation was determined from the slope of plots documenting the linear appearance of factor Xa with time. Control experiments established that inhibitors added to the initial reaction mixtures were either sufficiently diluted or were otherwise without obvious effect on the secondary measurements of Xa activity.
The rate of cleavage of factor X by VIIa-TF/PC in the presence of Corvas-pNA as an alternate peptidyl substrate for the VIIa-TF complex was determined in a coupled assay system by exploiting the ability of factor Xa formed to also catalyze Corvas-pNA hydrolysis. Reaction mixtures containing preassembled VIIa-TF/PC in Assay Buffer were initiated with a mixture of factor X and Corvas-pNA prepared immediately prior to use in the same buffer to achieve the indicated final concentrations. Following mixing by brief vibration, peptidyl substrate hydrolysis was monitored continuously by measuring absorbance at 405 nm. The velocity contribution of VIIa-TF to the increase in absorbance was negligible. The parabolic increase in absorbance as a function of time reflects the accumulation of factor Xa in the presence of the alternate peptidyl substrate for VIIa-TF. Progress curves were truncated and analyzed as described in detail (35) to infer the initial rate of Xa formation. Initial velocity studies of factor Xa formation in the absence of Corvas-pNA were conducted separately by the discontinuous approach described above.
Data Analysis-The kinetic studies were all conducted using a limiting concentration of factor VIIa and excess TF either in the form of TF/PCPS or TF/PC. Because the TF concentration was well above the established K d value for the VIIa-TF interaction in all cases (30, 36, 37) , the concentration of enzyme (VIIa-TF) is expected to correspond to the limiting concentration of VIIa. This was independently verified by documenting a linear dependence of the initial rate of either Corvas-pNA hydrolysis or factor X activation on increasing concentrations of VIIa, provided the TF concentration was in excess. Further verification of this expectation was obtained in separate experiments (not presented) showing similar rates of Corvas-pNA or factor X activation at identical concentrations of the limiting species when either VIIa or TF/PC was in excess. Thus, in all experiments, kinetic constants were calculated assuming that the concentration of enzyme (VIIa-TF) corresponded to the limiting concentration of VIIa present in the reaction mixture.
Steady state kinetic constants were extracted by fitting initial velocity data to the Henri-Michaelis-Menten equation or established steady state rate expressions for classical competitive or classical noncompetitive inhibition (38) by non-linear least squares analysis (39) . Alternate possibilities were evaluated by fitting the data to rate expressions for a series of different but relevant inhibition mechanisms and eliminating models that yielded poorer fits by the criteria described (40) or when the additional parameters required for more complex rate expressions were poorly determined without yielding a significant improvement in root mean squared deviation. The data are illustrated in a conventional double-reciprocal form solely to provide visual corroboration of the conclusions derived from the non-linear least squares analyses. With the exception of the coupled assay results, the data presented are representative of two or more similar experiments. Multiple kinetic constants are presented in some cases to indicate the results obtained with a different preparation of at least one macromolecular component.
RESULTS

Kinetics of Inhibition by Active Site-directed Ligands-PAB
is a well characterized reversible inhibitor of arginine-specific serine proteinases and has been used extensively to characterize the interactions of coagulation proteinases with inhibitors and substrates (19, 25, (41) (42) (43) . The x-ray structure of the benzamidine-trypsin complex is consistent with its intended mechanism of action (44) . The binding and dissociation of PAB to the active site of at least two coagulation enzymes has been established to be rapid (41, 43) . Thus, PAB is expected to act as a well behaved, competitive inhibitor of substrate binding to the active site of VIIa-TF.
Initial velocity studies of Corvas-pNA cleavage by VIIa-TF/ PCPS in the presence of different fixed concentrations of PAB confirmed these expectations (Fig. 1A) . PAB was found to act as a classical, complete competitive inhibitor of peptidyl substrate hydrolysis with a K i consistent with the values determined for the inhibition of other coagulation enzymes (25) . Increasing concentrations of PAB systematically increased the K m values for the peptidyl substrate without influencing the V max (Fig. 1A, inset) . These data indicate that PAB and peptidyl substrate bind in a mutually exclusive manner to the enzyme. This conclusion is consistent with the predominant role of S 1 -S 3 interactions at the active site of the enzyme in mediating productive interactions with peptidyl substrates (15) .
In contrast, initial velocity studies of factor X activation by VIIa-TF/PCPS indicated that PAB inhibited factor Xa formation by obviously decreasing the V max for the reaction without significantly influencing the K m for factor X (Fig. 1B) . These data could be adequately described by the rate expression for classical noncompetitive inhibition suggesting that PAB binding to the enzyme has no detectable effect on the binding of factor X and vice versa. However, previous studies have established that the apparent affinity of factor X for VIIa-TF assembled on PCPS membranes is dominated by the binding interactions between factor X and membranes that likely precedes the subsequent interactions between membrane-bound factor X and the enzyme (22) . Since the binding of PAB to the active site of VIIa within the enzyme complex is unlikely to affect the binding of factor X to membranes, it follows that classical noncompetitive inhibition observed under these conditions cannot be confidently interpreted in terms of specific effects of PAB on the enzyme-substrate interaction. This point is further reinforced by the observation that fits of the data to hyperbolic noncompetitive inhibition yielded marginally superior fits (data not shown) suggesting kinetic complexity.
Since factor X is not known to bind with significant affinity to membranes composed of pure PC (21), inhibition studies were repeated using TF reconstituted into PC membranes to facilitate interpretations. Initial velocity studies of the cleavage of Corvas-pNA in the absence or presence of increasing concentrations of PAB by VIIa-TF/PC yielded results that were indistinguishable from those obtained with PCPS membranes (Fig. 2A) . This observation is consistent with the membraneindependent nature of the ability of VIIa-TF complex to hydrolyze peptidyl substrates established in prior work (30, 45) . As expected, PAB acted as a classical, competitive inhibitor of peptidyl substrate cleavage by VIIa-TF/PC (Fig. 2A) .
The rate of factor X cleavage by VIIa-TF/PC was reduced in comparison to the rate of the same reaction catalyzed by VIIa-TF/PCPS (Fig. 2B) . The decreased rate arose from a large increase in the K m for factor X, whereas the V max for the two enzymes was similar. This finding is consistent with the role of the substrate-membrane interaction in determining the appar-ent affinity of the enzyme for the membrane-binding substrate established in this and other analogous reaction systems of coagulation (22, 36, 46) . Classical noncompetitive inhibition of factor X activation by PAB was observed even in the absence of high affinity interactions between factor X and the membrane surface (Fig. 2B) . Since the K i determined for PAB under these conditions was in tolerable agreement with the values determined in all the previous measurements, the data indicate that PAB binding to the active site of VIIa within the enzyme complex excludes peptidyl substrate binding but has no obvious effect on the perceived affinity of the enzyme for the protein substrate, even when affinity term is not expected to be compromised by kinetic complexities associated with the factor X-membrane interaction.
Kinetics of Inhibition by an Alternate Peptidyl SubstrateQualitative differences in the mechanisms of inhibition of peptidyl substrate versus protein substrate cleavage by VIIa-TF/PC were further investigated by inhibition studies of factor X activation by an alternate peptidyl substrate. Inhibition was evaluated with different fixed concentrations of Corvas-pNA as an indicator substrate in coupled assays of factor Xa formation. This approach permits the initial rate of factor Xa formation to be inferred in the presence of a peptidyl substrate that is also cleaved by the VIIa-TF/PC complex. The rate of factor Xa formation was significantly reduced in the presence of high, fixed concentrations of Corvas-pNA, relative to the K m for VIIa-TF/PC (Fig. 3) . The initial velocity data were adequately described by the rate expression for classical noncompetitive inhibition (Fig. 3) , implying that inhibition by the alternate peptidyl substrate arises from a decreased V max for Xa formation, whereas the K m for the protein substrate remains unchanged. The K i , determined from these experiments, was in good agreement with the measured K m for the cleavage of Corvas-pNA by VIIa-TF (Figs. 1A and 2A ). These observations lead to the conclusion that the affinity of the enzyme for the protein substrate is not detectably altered even when a peptidyl substrate is productively bound to the active site of VIIa within the extrinsic Xase complex.
The results of inhibition studies with active site-directed ligands are summarized in Table I . Although PAB was a complete, competitive inhibitor of peptidyl substrate cleavage of VIIa-TF, this serine proteinase inhibitor uniformly acted as a classical noncompetitive inhibitor of factor X activation. Whereas measurements with TF/PCPS are provided for reference, membrane binding by factor X in this system is expected to dominate the perceived affinity of the substrate for the enzyme. Consequently, the K m for factor X cleavage by VIIa-TF/PC is more likely to reflect the affinity for the productive enzyme-substrate interaction. The fact that PAB acts as a classical noncompetitive inhibitor of factor X activation on PC membranes suggests that inhibitor binding does not affect protein substrate binding even in the absence of additional interactions between factor X and membranes. This conclusion is further supported by results of inhibition studies using CorvaspNA as an alternate substrate (Table I) . Collectively, the data suggest a qualitative difference in the mechanism of recognition of the peptidyl substrate relative to factor X by the VIIa-TF complex. Occupation of the active site of VIIa within the extrinsic Xase complex excludes peptidyl substrate binding but does not noticeably influence the affinity of the enzyme for factor X.
Kinetics of Inhibition by Factor X Derivatives-The inhibition studies, described above, suggest the possibility that a major determinant for protein substrate affinity derives from possible enzyme-substrate interactions removed from the active site of the enzyme and from the residues surrounding the scissile bond in the substrate. This possibility was further tested by inhibition studies with a recombinant factor X derivative (X R15Q ) where the P 1 arginine was replaced with glutamine (20) . Because this recombinant derivative also contains Ser 195 substituted with alanine and would yield a catalytically inactive product, possible cleavage of X R15Q by VIIa-TF/PC was evaluated in initial studies by SDS-polyacrylamide gel electrophoresis analysis of quenched samples (26) . As has previously been established (20) , there was no detectable cleavage of the mutant substrate by the extrinsic Xase complex. Analysis by quantitative densitometry indicated that possible cleavage of X R15Q by VIIa-TF/PC was below detection limits or at least 50-fold slower than that of plasma-derived factor X. This result is expected based on the established preference of factor VIIa for substrates with an arginine side chain at the P 1 position and with the presumed importance of substrate interactions at the primary specificity pocket for bond cleavage (15, 47) .
Initial velocity studies of factor X activation by VIIa-TF/PC indicated that the uncleavable X R15Q derivative was an inhibitor of factor Xa formation (Fig. 4) . Inhibition was adequately described by the rate expression for complete competitive inhibition (Fig. 4) , and the derived K i was comparable to the K m for native factor X. The data indicate that despite compromised interactions between the mutant derivative and the active site of VIIa within the VIIa-TF/PC complex, X R15Q binds to the enzyme complex with an affinity that is comparable to the native substrate and excludes the binding of factor X. These observations suggest that the docking of substrate structures surrounding the scissile bond with the active site of the enzyme are unlikely to play a major role in determining the perceived affinity of the VIIa-TF complex for factor X.
This possibility was further investigated by inhibition studies using Xa i . Xa i was found to act as a complete, competitive inhibitor of factor X activation by VIIa-TF/PC (Fig. 5) . This implies that the product and substrate bind in a mutually exclusive manner to the VIIa-TF complex. Since the activation peptide, bearing residues N-terminal to the activation site, is eliminated by purification following preparative activation of factor X (18), the data suggest that interfering with substrate interactions distinct from those provided by residues preceding the scissile bond is sufficient to exclude substrate binding.
The kinetic constants obtained in the inhibition studies with factor X and Xa derivatives are summarized in Table II . The uncleavable X R15Q derivative was found to inhibit factor X activation with a K i comparable to the K m for the native substrate. This implies that replacement of the P 1 arginine with glutamine yields a zymogen derivative that is not cleaved by VIIa-TF because of a V max defect, even though active site docking interactions are likely compromised in this mutant. In contrast, inhibition by the catalytically inactivated product (Xa i ) was characterized by a 3-4-fold reduced affinity for VIIa-TF. This modest but reproducibly higher K i raises the possibility that either there is some minor contribution from interactions between residues in the activation peptide region and the enzyme to macromolecular substrate affinity or that established structural changes that accompany the zymogen-protease transition modestly perturb interactions at sites removed from the catalytic site of the enzyme. Collectively, the data are consistent with the principal conclusion that the affinity of VIIa-TF for the macromolecular substrate is predominantly determined by interactions between the protein substrate and enzymic sites distinct from the active site.
Kinetic Model for Factor X Activation by VIIa-TF-The inhibition studies indicate that protein substrate recognition by the VIIa-TF complex is minimally achieved through two sequential steps (Scheme 1). The reaction between the protein substrate (S) and the VIIa-TF complex (E) derives from initial interactions between enzymic sites distinct from the active site and complementary sites on the protein substrate removed from structures surrounding the scissile bond. Since interactions between the substrate and the active site of the enzyme are required for catalysis, the bimolecular reaction must be followed by an intramolecular binding step that permits structures surrounding the cleavage site to dock with the active site of the enzyme prior to bond cleavage. As a result of this twostep binding process, ligands (I) that bind to the active site of factor VIIa within the complex act as classical noncompetitive inhibitors because they do not affect ES formation. Equivalently, exosite-dependent binding of S to E does not alter I binding (␣ Х 1, Scheme 1). The intramolecular binding step, determined by K s *, requires prior dissociation of small molecule inhibitors targeting the active site. Consequently, ligands such as I act as inhibitors because they interfere with the second of the two binding steps in protein substrate recognition. As I acts as a classical noncompetitive inhibitor of factor X activation, it follows that the perceived affinity of E for S is almost entirely determined by exosite interactions in the first binding step. Following cleavage, the product (factor Xa) remains associated with the exosite and must dissociate from the enzyme for subsequent rounds of catalysis. This explains the ability of the product to act as a classical competitive inhibitor of factor X activation. The release of the activation peptide following bond cleavage is illustrated for the purpose of convenience. The present data cannot distinguish between this and the alternate possibility that the activation peptide remains bound to factor Xa following bond cleavage. In this case, product release following catalysis would require the dissociation of the factor Xa-activation peptide binary complex.
Provided that additional steps are not necessary to describe factor X activation, the relationship between the observed kinetic constants for factor X activation and the intrinsic con- stants (Scheme 1) can be readily illustrated using the rapid equilibrium assumption shown in Equations 1 and 2,
The equilibrium dissociation constant for the intramolecular binding step modifies both the V max and K m terms. Consequently, binding interactions at the active site can contribute to and modulate the V max for the reaction. As the data indicate that the perceived affinity of factor X for VIIa-TF is dominated by exosite interactions (i.e. K m(obs) Х K s ), it also follows that K s * is likely to be greater than 1, provided the rapid equilibrium assumption holds. These points provide a reasonable quantitative accounting for factor X activation by the VIIa-TF complex.
DISCUSSION
The present study provides evidence for an obvious difference between the mechanism(s) underlying the productive recognition of an oligopeptidyl substrate versus factor X by the VIIa-TF complex. This distinction arises from the predominant contribution of interactions at enzymic sites, distinct from the active site, to the perceived affinity for factor X. In contrast, as expected from structural studies of VIIa-TF as well as of other serine proteinases (9, 15), the affinity for peptidyl substrates arises from interactions at the active site of factor VIIa within the extrinsic Xase complex. These conclusions are evident from the ability of reversible active site-directed proteinase inhibitors, typified by aminobenzamidine, to act as competitive inhibitors of peptidyl substrate cleavage yet act as classical noncompetitive inhibitors of factor X activation. This experimental framework, initially developed in studies with prothrombinase (19) and extended in the present work to factor X activation, appears to provide a simple yet powerful approach to assess the relative contributions of enzyme-substrate interactions at the active site versus exosites to macromolecular substrate recognition.
The two-step model for the productive interaction of factor X with the VIIa-TF complex (Scheme 1) provides a series of insights into the mechanisms underlying the specific recognition of this protein substrate. The observation of classical noncompetitive inhibition implies that the predominant kinetic pathway for factor X binding proceeds through exosite interactions followed by an active site docking step prior to substrate cleavage. Productive substrate binding through an additional pathway incorporating the two steps in the opposite order would lead to significant deviation from classical noncompetitive inhibition. That this is not observed implies that such an alternate pathway does not contribute detectably to the observed kinetics of the reaction under the conditions examined. It is possible that productive docking of the factor X at the active site of the enzyme is somehow facilitated by the initial exosite interactions. This possibility is consistent with the tentative conclusion that the intramolecular binding interactions at the active site are likely to be unfavorable. Assuming that this preliminary conclusion is sustained by further work, it would follow that binding specificity for the protein substrate is predominantly determined by exosite interactions and not from interactions at the active site. These ideas indicate that regions of VIIa and TF spatially removed from the catalytic site of VIIa within the complex, identified in previous studies to be important for factor X activation (12) (13) (14) 16) , may actually play a primary rather than ancillary role in determining the binding specificity for the protein substrate.
The primary contribution of substrate binding interactions at the active site appears to be to the V max of the reaction. This provides a rational explanation for the observation that a series of recombinant VIIa derivatives with substitutions at residues implicated in substrate interactions at the active site exhibit a decreased V max but unchanged K m for factor X activation (20, 48) . In the present work, this conclusion is evident from the inhibition studies with active site-directed reagents as well as the finding that the uncleavable X R15Q binds to VIIa-TF with an affinity equivalent to that of native factor X. In the case of X R15Q , the equilibrium dissociation constant for the exosite-dependent interaction (K s , Scheme 1) would be unchanged from native factor X, but the inability of glutamine to adequately SCHEME 1. Kinetic pathway for factor X activation by VIIa-TF. The scheme illustrates the conversion of factor X (S) to Xa (P) and the release of the activation peptide (AP) by the VIIa-TF/PC complex (E) in the presence of an active site-directed reversible inhibitor (I). K s , K i , and K p denote equilibrium dissociation constants for the binding of S, I, and P to E, respectively, with ␣ Х 1. K s * is the equilibrium dissociation constant for the unimolecular step that leads to interactions between S and E at the active site of the enzyme. The catalytic step is denoted by k cat . The formation of ES derives from exosite interactions illustrated between regions of the enzyme removed from the catalytic site and complementary regions of the substrate removed from the scissile bond without specific knowledge of where these sites may lie on the interacting species. substitute for the P 1 arginine for interactions at the primary specificity site would greatly increase the equilibrium dissociation constant for the active site interactions (K s *, Scheme 1). It is obvious from Equations 1 and 2 that these changes will affect the V max but not the perceived affinity of X R15Q for VIIa-TF. Paradoxically, the uncleavable nature of X R15Q arises from a V max defect even though the intent of this mutation is to abrogate binding interactions at the active site. Therefore, less drastic substitutions at the P 2 -P 4 residues will likely yield factor X derivatives that are appropriate substrates for VIIa-TF with the same K m as native factor X but possibly with an altered V max . This idea challenges the presumed specific enzymic recognition of residues preceding the scissile bond in the zymogen substrate as a principal basis for protease specificity in blood coagulation.
Competitive inhibition of factor X activation by Xa i , purified to remove the activation peptide, implies that the proteinase product possesses sufficient structural information to compete effectively for exosite interactions with the substrate (Scheme 1). The modestly reduced affinity of Xa i for VIIa-TF binding relative to the K m for factor X suggests that there is either some small contribution of the activation peptide domain to substrate binding or that the zymogen to proteinase transition (49) somehow modestly perturbs the ability of the product to interact with the enzymic exosite. In either case, the present work provides documented evidence for the ability of factor Xa to bind to VIIa-TF. This observation provides a potential explanation for the major enhancing effects of factor Xa on the rate and equilibrium constant for the inhibition of VIIa-TF by TFPI (6) . It is possible that the initial formation of the Xa-TFPI binary complex transforms TFPI from an inhibitor species with limited and relatively weak interactions with the catalytic site of VIIa-TF to one with the added energetic contributions of the exosite-dependent binding of Xa to VIIa-TF, thereby leading to a vast increase in inhibitory potency. The kinetic conclusions of the present work (Scheme 1) also provide a credible explanation for the proposal that the principal inhibitory target for TFPI during factor X activation is likely factor Xa bound to the VIIa-TF complex (26) .
Scheme 1 predicts that all ligands that only occlude active site-dependent binding interactions of the substrate with VIIa-TF will uniformly act as classical noncompetitive inhibitors of factor X activation. This point has important implications for the targeting of the active site of factor VIIa by reversible inhibitors for therapeutic purposes (50) . Based on our findings, such inhibitors are not expected to interfere with the bimolecular interaction between factor X and the enzyme but instead interfere with binding interactions at the active site that occurs as an intramolecular step. Efficient blocking of such intramolecular binding interactions by reversibly interacting ligands is expected to be thermodynamically difficult to achieve (51) .
A similar experimental approach pursued with studies of protein substrate cleavage by the analogous prothrombinase complex of coagulation has yielded conclusions that are remarkably similar to those of the present work (19, 35) . Thus, it appears that exosite-dependent interactions play a predominant role in determining the affinity for the protein substrate and kinetics of function of at least two enzyme complexes of the blood coagulation cascade. Specific recognition of the protein substrate by interactions at enzymic exosites may represent a prevalent strategy by which specific cleavage of protein substrates is accomplished by the coagulation enzyme complexes. Thus, these complexes may have evolved their distinctive specificities not only through changes to residues surrounding the catalytic site but also by changes to residues in exosites that influence binding specificity for the protein substrate.
